[New AMM: Nivolumab for advanced oesophageal squamous cell carcinomia after first line of chemotherapy]

Mathilde Reich; Clelia Coutzac

doi:10.1016/j.bulcan.2020.12.005

[New AMM: Nivolumab for advanced oesophageal squamous cell carcinomia after first line of chemotherapy]

Bull Cancer. 2021 Mar;108(3):228-229. doi: 10.1016/j.bulcan.2020.12.005. Epub 2021 Jan 30.

[Article in French]

Authors

Mathilde Reich¹, Clelia Coutzac²

Affiliations

¹ Institut Curie, hôpital René-Huguenin, département d'oncologie médical, 35, rue Dailly, 92210 Saint-Cloud, France. Electronic address: reich.mathilde@gmail.com.
² Centre Léon Bernard, département d'oncologie médicale, 28, rue Laënnec, 69008 Lyon, France.

PMID: 33531154
DOI: 10.1016/j.bulcan.2020.12.005

No abstract available

Keywords: Carcinome épidermoïde de l’œsophage; Immune checkpoint inhibitor; Inhibiteurs de point de contrôle immunologique; Nivolumab; Oesophageal squamous cell carcinoma; PD-1; PD1.

Publication types

Letter

MeSH terms

Antineoplastic Agents, Immunological / adverse effects
Antineoplastic Agents, Immunological / therapeutic use*
Clinical Trials as Topic
Esophageal Neoplasms / drug therapy*
Esophageal Neoplasms / pathology
Europe
Humans
Immune Checkpoint Inhibitors / adverse effects
Immune Checkpoint Inhibitors / therapeutic use*
Nivolumab / adverse effects
Nivolumab / therapeutic use*

Substances

Antineoplastic Agents, Immunological
Immune Checkpoint Inhibitors
Nivolumab